Proove's genetic tests predict risk of addiction, pain perception, and response to opioids...
Irvine, CA (PRWEB) July 21, 2015
Proove Biosciences, a commercial and research leader in Personalized Medicine, shared new clinical research at the International Conference on Opioids (ICOO), June 7-9, 2015. The 3-day event took place at the Joseph B. Martin Conference Center at the Harvard Medical School in Boston, MA. Presented by the Journal of Opioid Management, ICOO boasts a focus on the clinical application of opioid pharmacology - with pain medicine’s most eminent professionals leading the conversation.
Proove Biosciences presented five posters, all of which are dedicated to the study of how genetic variations influence the effect of opioids, on June 8th 2015. The Study to Comprehensively Calculate Risk of Aberrant Behavior to Opioids by Incorporating Genetics and Phenotypic Risk Factors in Pain Patients uses a scoring algorithm to determine the predictability of aberrant behavior to opioids while incorporating phenotypic risk factors into the analysis.
The Role of Genetics in Risk of Opioid Abuse: Relationship between Genetics and Opioid Risk Tool study is to understand the relationship between genetics and the Opioid Risk Tool, the gold standard tool used to predict risk of opioid abuse by taking into account phenotypic risk factors. The ORT tool has been developed to assess risk of aberrant and negative behaviors that may possibly take place while using prescription opioids, such as abuse, misuse, and addiction. If designated as high-risk to be more likely to abuse opioids, what is the relationship to genetics?
The Role of Genetics in Risk of Opioid Abuse: Relationship Between Genetics and SOAPP-R Test study is designed to help understand the relationship between genetics and the SOAPP-R (the Screener and Opioid Assessment for Patients with Pain), a self-questionnaire to help physicians evaluate a patients’ risk for potentially becoming addicted to opioids or suffering from adverse drug events. While many studies exist to show that genetics play an important role in the response to opioid medications, the Genetics and SOAPP-R study intends to further explore the relationship between genetics and the widely used SOAPP-R questionnaire.
The Genetics and Drug Response: Study on the Influence of Genetics in Individual Variations in Response to Hydromorphone Use is to determine if genetics influence an individual’s response to the hydromorphone analgesic opioid. Although hydromorphone is 6-8 times more potent than morphine, it is generally thought to have lower risk of dependence than morphine. Since hydromorphone sometimes has unintended side effects such as euphoria, itching, myositis (swelling and inflammation), and physical tolerance, Proove Biosciences hopes to explore the impact of genetics on drug response in order to improve the prescription and efficacy of the medication.
Genetics and Drug Response: Study on the Influence of Genetics in Individual Variations in Response to Suboxone Use aims to determine if genetics influence an individual’s response to Suboxone, a brand name for the opioid buprenorphine. Suboxone is used to treat opioid addiction and to treat moderate acute pain in non-opioid tolerant patients. Since genetics may account for 20-90% of an individual's’ drug response, Proove Biosciences goal is to find out which genes may have an influence of an individual’s reaction to Suboxone.
“At the International Conference on Opioids, the general consensus of physicians I spoke to was that pharmacogenomics is unproven and has value only in cases of aberrant metabolizers. When I told them about our genetic tests predicting risk of addiction, pain perception, and response to opioids it was a whole new story! As one of the physicians with a large practice said: ‘This would be incredibly valuable in my practice, we would order it on everyone,’” said Maggie Hopkins, MD, a Proove Biosciences’ Clinical Science Liaison and the presenting author of the above studies.
About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).